[go: up one dir, main page]

BRPI0817927A2 - Comprimidos orodispersiveis - Google Patents

Comprimidos orodispersiveis

Info

Publication number
BRPI0817927A2
BRPI0817927A2 BRPI0817927-1A BRPI0817927A BRPI0817927A2 BR PI0817927 A2 BRPI0817927 A2 BR PI0817927A2 BR PI0817927 A BRPI0817927 A BR PI0817927A BR PI0817927 A2 BRPI0817927 A2 BR PI0817927A2
Authority
BR
Brazil
Prior art keywords
orodispersible
pills
orodispersible pills
Prior art date
Application number
BRPI0817927-1A
Other languages
English (en)
Inventor
Carmen Úbeda Pérez
Ignacio Diez Martin
Pablo Pablo Alba
Original Assignee
Lesvi Laboratorios Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lesvi Laboratorios Sl filed Critical Lesvi Laboratorios Sl
Publication of BRPI0817927A2 publication Critical patent/BRPI0817927A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
BRPI0817927-1A 2007-10-01 2008-09-30 Comprimidos orodispersiveis BRPI0817927A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07380265 2007-10-01
US97716607P 2007-10-03 2007-10-03
PCT/EP2008/063068 WO2009043844A2 (en) 2007-10-01 2008-09-30 Orodispersible tablets

Publications (1)

Publication Number Publication Date
BRPI0817927A2 true BRPI0817927A2 (pt) 2015-04-07

Family

ID=38962587

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817927-1A BRPI0817927A2 (pt) 2007-10-01 2008-09-30 Comprimidos orodispersiveis

Country Status (11)

Country Link
US (3) US9623010B2 (pt)
EP (2) EP2205213A2 (pt)
JP (1) JP2010540588A (pt)
KR (1) KR101626873B1 (pt)
BR (1) BRPI0817927A2 (pt)
CA (1) CA2703501C (pt)
ES (1) ES2645255T3 (pt)
PL (1) PL2572705T3 (pt)
PT (1) PT2572705T (pt)
WO (1) WO2009043844A2 (pt)
ZA (1) ZA201002255B (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DK2151235T3 (da) * 2008-07-21 2011-04-11 Falk Pharma Gmbh Farmaceutisk formulering til behandling af den øvre fordøjelseskanal
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
CN102114014A (zh) * 2009-12-30 2011-07-06 北京德众万全药物技术开发有限公司 一种含有阿莫曲坦的药物组合物
EP2387993B1 (en) * 2010-05-21 2012-11-07 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
FR2962331B1 (fr) * 2010-07-06 2020-04-24 Ethypharm Forme pharmaceutique pour lutter contre la soumission chimique, methode la mettant en oeuvre
WO2012014012A1 (es) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
BR112013002667B1 (pt) 2010-08-04 2020-02-04 Thomas Julius Borody composições para transplante da flora intestinal e métodos para fazê-las e usá-las e dispositivos para administrá-las
MX355760B (es) 2010-12-13 2018-04-27 Salix Pharmaceuticals Inc Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas.
JP2014507481A (ja) 2011-03-09 2014-03-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 結腸微生物相移植のための組成物及び方法
JP6208931B2 (ja) * 2011-09-07 2017-10-04 三菱商事フードテック株式会社 硬度を高めた口腔内崩壊錠およびその製造方法
WO2013095314A1 (en) * 2011-12-19 2013-06-27 Mahmut Bilgic Pharmaceutical formulations comprising risperidone
WO2013100876A1 (en) * 2011-12-27 2013-07-04 Mahmut Bilgic Risperidone formulations
WO2013172805A1 (en) * 2012-05-14 2013-11-21 Mahmut Bilgic New orodispersible tablet formulations of olanzapine
WO2013175508A2 (en) 2012-05-24 2013-11-28 Medreich Limited Stable pharmaceutical composition of aripiprazole
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
CN104540521A (zh) 2012-06-04 2015-04-22 高拉夫·阿格拉沃尔 用于治疗克罗恩氏病和相关病况以及感染的组合物和方法
ES2717282T3 (es) 2012-07-27 2019-06-20 Redhill Biopharma Ltd Formulaciones y métodos para fabricar formulaciones para su uso en la evacuación colónica
MX392839B (es) 2012-11-30 2025-03-24 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
JP2016117651A (ja) * 2013-04-16 2016-06-30 株式会社ダイセル 小動物への投与に適した速崩壊錠とその簡便な製造方法
JP2016117652A (ja) * 2013-04-16 2016-06-30 株式会社ダイセル 小児への投与に適した速崩壊錠とその簡便な製造方法
CN105307654B (zh) 2013-04-30 2022-06-07 托马斯·朱利叶斯·波洛迪 用于治疗微生物区系相关的精神病况和疾病的组合物和方法
JP2014218472A (ja) * 2013-05-10 2014-11-20 エルメッド エーザイ株式会社 オランザピン乃至その塩含有錠剤
US20160136091A1 (en) * 2013-07-19 2016-05-19 Sanwa Kagaku Kenkyusho Co., Ltd. Orally Disintegrating Tablet
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
WO2015045604A1 (ja) * 2013-09-30 2015-04-02 富士フイルム株式会社 口腔内崩壊錠
EP3065700A1 (en) * 2013-11-07 2016-09-14 Synthon B.V. Orodispersible pharmaceutical compositions comprising aripiprazole
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
HRP20190677T4 (hr) 2013-12-23 2023-02-03 Dr. Falk Pharma Gmbh Optimizirana farmaceutska formula za liječenje upalnih promjena u jednjaku
WO2015145459A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
JP2017519015A (ja) 2014-07-02 2017-07-13 オブセヴァ エス．エー． Ｏｔ−ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）−５−（ヒドロキシメチル）−１−［（２’−メチル−１，１’−ビフェニル−４−イル）カルボニル］ピロリジン−３−オン о−メチルオキシム
US20160008310A1 (en) 2014-07-11 2016-01-14 Azanta A/S Misoprostol dispersible tablet
JP6532529B2 (ja) * 2014-07-11 2019-06-19 アサンタ・デンマーク・アー／エス ミソプロストール分散性錠剤
BR112017024264B1 (pt) 2015-05-14 2022-07-12 Crestovo Holdings Llc Composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para sua administração
CN114470009A (zh) 2015-05-22 2022-05-13 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
EP3352773B1 (en) 2015-09-24 2024-12-18 San Diego State University (SDSU) Foundation DBA San Diego State University Research Foundation Antibacterial and protective bacteriophage formulations and methods for making and using them
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CN110831606A (zh) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
AU2018272048B2 (en) 2017-05-26 2024-04-04 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
KR102084602B1 (ko) * 2018-11-08 2020-03-04 주식회사 서흥 발포성 및 안정성이 향상된 구강 세정용 발포정
CN113164396B (zh) 2018-11-26 2023-11-03 宝洁公司 含有硫辛酸的固体药物制剂及其用途
EP3766483A1 (en) * 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
JP2022541795A (ja) 2019-07-19 2022-09-27 フィンチ セラピューティクス ホールディングス エルエルシー 胃腸障害の治療のための方法および産物
CN110477378B (zh) * 2019-08-02 2022-11-29 大连医诺生物股份有限公司 含脂溶性成分的口溶型直饮粉及其制备方法
CN112546002B (zh) * 2020-12-07 2022-08-05 北京斯利安药业有限公司 一种生物素口崩片及其制备方法
KR102413426B1 (ko) 2020-12-21 2022-06-29 주식회사 씨엠지제약 나라트립탄을 포함하는 구강용해 필름 제형
TR2022020580A2 (tr) * 2022-12-27 2023-01-23 Atatürk Üni̇versi̇tesi̇ Fi̇kri̇ Mülki̇yet Haklari Koordi̇natörlüğü Döner Sermaye İşletmesi̇ Gri̇p, soğuk alginliği ve alerji̇k semptomlarin tedavi̇si̇nde kullanilabi̇lecek ağizda dağilan tablet (odt) formülasyonlari

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
NZ507271A (en) 1998-03-06 2003-03-28 Eurand Internat S Fast disintegrating tablets
US20020071864A1 (en) 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
US20030161879A1 (en) 1999-06-29 2003-08-28 Shinji Ohmori Tablets quickly disintegrating in mouth
US20020076437A1 (en) 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
US6583722B2 (en) * 2000-12-12 2003-06-24 Kimberly-Clark Worldwide, Inc. Wetness signaling device
US6610266B2 (en) 2001-11-28 2003-08-26 Michael C. Withiam Calcium metasilicates and methods for making
AU2003221326A1 (en) 2002-03-06 2003-09-16 Kyowa Hakko Kogyo Co., Ltd. Tablets quickly disintegrating in oral cavity
US6984377B2 (en) * 2002-05-29 2006-01-10 J. M. Huber Corporation Oral care products comprising calcium metasilicates
ES2199061B1 (es) * 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
WO2005037254A1 (ja) 2003-10-15 2005-04-28 Fuji Chemical Industry Co., Ltd. 口腔内速崩壊性錠剤
US20050244347A1 (en) * 2004-04-30 2005-11-03 Mehra Dev K Oral care products comprising calcium phosphates
ES2255429B1 (es) * 2004-10-25 2007-08-16 Italfarmaco, S.A. Composiciones farmaceuticas bucodispersables.
EP1681048A1 (en) 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Orally disintegrating composition of olanzapine or donepezil
DE102005009241A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
JP4944467B2 (ja) * 2005-03-24 2012-05-30 第一三共株式会社 医薬用組成物
KR20140065482A (ko) * 2005-03-24 2014-05-29 다이이찌 산쿄 가부시키가이샤 의약용 조성물
US20070202163A1 (en) 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
JP5535616B2 (ja) 2006-03-31 2014-07-02 ルビコン リサーチ プライベート リミテッド 口腔内崩壊錠剤のための直接圧縮性複合材
EP1977734A1 (en) * 2007-04-03 2008-10-08 Royal College of Surgeons in Ireland A method of producing fast dissolving tablets
CA2700224A1 (en) 2007-09-19 2009-03-26 Asahi Breweries, Ltd. Method of producing granules containing natural products derived substance such as chinese orthodox medicine extracts, crude drug extracts, and extracts derived from natural substances, and producing a tablet in use of said granules

Also Published As

Publication number Publication date
US20170157053A1 (en) 2017-06-08
WO2009043844A2 (en) 2009-04-09
EP2572705B1 (en) 2017-09-13
CA2703501C (en) 2017-06-13
KR101626873B1 (ko) 2016-06-02
WO2009043844A3 (en) 2009-06-18
JP2010540588A (ja) 2010-12-24
KR20100077187A (ko) 2010-07-07
EP2205213A2 (en) 2010-07-14
EP2572705A1 (en) 2013-03-27
US20100297031A1 (en) 2010-11-25
US20160310470A1 (en) 2016-10-27
PT2572705T (pt) 2017-11-08
ES2645255T3 (es) 2017-12-04
PL2572705T3 (pl) 2018-01-31
US9623010B2 (en) 2017-04-18
ZA201002255B (en) 2011-12-28
CA2703501A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
BRPI0817927A2 (pt) Comprimidos orodispersiveis
DK4218732T3 (da) Tabletter omfattende eltrombopag-olamin
BRPI0920521A2 (pt) combinação farmacêutica
EP2156752A4 (en) SWEETENER
ATE501136T1 (de) Imidazopyridinone
BRPI0808889A2 (pt) Comprimido desintegrante oral
BRPI0810495A2 (pt) difenil-di-hidro-imidazopiridinonas
BRPI0812916A2 (pt) Chupeta
BRPI0811451A2 (pt) Exopolissacarídeo
BRPI0814519A2 (pt) Organopolissiloxano
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
BRPI0812840A2 (pt) 2-imidazolinas
DE502007005910D1 (de) Tablettenabfüllvorrichtung
AT505058A3 (de) Türschliesssystem
DE112008001742A5 (de) Sensoranordnung
DK2007384T3 (da) Orodispergerbare domperidontabletter
DE602007010950D1 (de) Dosierpumpe
DK2272763T3 (da) Blisterpakning-dispensermaskine
DE112008000345A5 (de) Sensoranordnung
DE112008001216A5 (de) Magnetronplasmaanlage
DE112008002200A5 (de) Sperrsynchronisiervorrichtung
DE102007038931A8 (de) Fadenlagennähwirkstoffe
DK1970496T3 (da) Doseringsarrangement
ES1064046Y (es) Multiventuri dosificador
DE112008002909A5 (de) Verwahrbehältnis

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law
B06I Technical and formal requirements: publication cancelled
B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal
B09B Decision: refusal

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL